Effectiveness of measures to prevent needlestick injuries among ...

More documents

Recommendations

Info

5 Cost effectiveness estimating costs to be between US $ 532 and US $ 3,437 (if the source patient was known seropositive). In her final cost-benefit analysis, Hatcher used the average of the two California OSHA estimates, arriving at a total of US $ 3,033. The reason for substituting state OSHA estimates for institution-specific costs estimates was not explained. With annual purchase costs increasing by $ 10,000 and an estimated annual reduction in NSI of 24, the author calculated a net savings of more than US $ 62,000 [81]. 5.3 Summary In general, the reported costs of NSI are underestimated. Although calculations usually included costs of testing and PEP, and sometimes the cost of labor and lost work time, costs associated with seroconversion were generally not considered. Reasons included: a) only a relatively small subset of HCW would be affected; b) the possible costs depend on the situation (age, health status, type of infection, severity of disease) of the HCW [22]; and c) from a hospital-based view, these costs are usually borne by a third party payer, e. g. workers compensation or a health insurance plan, and not the employer himself [23]. It is difficult to predict how even these underestimated costs might be borne on a societal level. For example, the costs of antiviral therapy after HCV seroconversion have been estimated to be € 10,000 for 24 weeks or € 20,000 for 42 weeks in Ger- many [20]. A possible additional cost for an HCV infected HCW is a liver transplant – estimated to be around € 100,000 in Germany [20] and $ 140,000 in the US [103]. In the US, the average annual costs for treating a person with HIV was been estimated in 1996 to be between $ 20,000 and $ 25,000 [22]. The costs associated with the introduction of safer devices were also underestimated. Costs associated with inventory changeover, healthcare worker training, and device evaluations were usually not considered in any of the available cost or cost-benefit analysis. Report „Needlestick injuries“ 68
5 Cost effectiveness That the majority of the available empirical cost-benefit analysis discussed the imple- mentation of needleless IV systems might be due to the fact that these systems offer the opportunity for a complete elimination of NSI in this area. Even when the same type of equipment was under consideration, the reported results were in conflict due to differ- ences in calculations: some investigators were able to offset the higher purchase costs associated with the safety devices with the smaller number of sets needed, while others were not. Finally, most of the cost-benefit evaluations were done during the early 1990s; their relevance to the current day cannot be assessed. The purchase prices for both the safer devices and the standard devices are likely to have changed, in addition to the cost of other factors contributing to the total cost of a NSI. Report „Needlestick injuries“ 69
Page 1:
Effectiveness of measures to preven
Page 4 and 5:
Authors: Sandra I. Sulsky, Thomas B
Page 6 and 7:
Wirksamkeit und Wirtschaftlichkeit
Page 8 and 9:
Eficacia y rentabilidad de medidas
Page 10 and 11:
5 Cost effectiveness ..............
Page 13 and 14:
Preface Preface It has long been re
Page 15 and 16:
1 Introduction 1 Introduction Altho
Page 17 and 18:
1 Introduction scientific laborator
Page 19: 1 Introduction To complete each of
Page 23 and 24: 3 Descriptive epidemiology of NSI 3
Page 25 and 26: 3 Descriptive epidemiology of NSI a
Page 27 and 28: 3 Descriptive epidemiology of NSI c
Page 29 and 30: 3 Descriptive epidemiology of NSI s
Page 31 and 32: 3 Descriptive epidemiology of NSI h
Page 33 and 34: 4 Intervention program evaluation 4
Page 35 and 36: 4 Intervention program evaluation u
Page 37 and 38: 4 Intervention program evaluation d
Page 39 and 40: 4 Intervention program evaluation (
Page 41 and 42: 4 Intervention program evaluation c
Page 43 and 44: 4 Intervention program evaluation t
Page 45 and 46: 4 Intervention program evaluation a
Page 47 and 48: 4 Intervention program evaluation d
Page 53 and 54: 4 Intervention program evaluation b
Page 55 and 56: 4 Intervention program evaluation 4
Page 57 and 58: 4 Intervention program evaluation C
Page 59: 4 Intervention program evaluation a
Page 62 and 63: 5 Cost effectiveness Both costs and
Page 64 and 65: 5 Cost effectiveness 21 % by using
Page 66 and 67: 5 Cost effectiveness the high HBV v
Page 68 and 69: 5 Cost effectiveness After the impl
Page 73 and 74: 6 Discussion 6 Discussion This repo
Page 75: 7 Recommendations 7 Recommendations
Page 78 and 79: 8 Bibliography [12] Verordnung übe
Page 80 and 81: 8 Bibliography A retrospective stud
Page 82 and 83: 8 Bibliography [48] Gartner, K.: Im
Page 84 and 85: 8 Bibliography [66] O'Connor, R. E.
Page 86 and 87: 8 Bibliography [86] Thomas, S.; Aga
Page 89 and 90: Tables Table 1: Overview of prevent
Page 91 and 92: Tables Table 3: Distribution of cou
Page 93 and 94: Tables Table 5: Distribution of nee
Page 95 and 96: Tables Table 7: Activity during nee
Page 97 and 98: Tables Table 9: Screening Criteria
Page 99 and 100: Tables Table 11: Quality indicators
Page 101 and 102: Tables Table 13: Examples of estima
Page 103 and 104: Annex 1: Glossary and abbreviations
Page 105 and 106: Annex 1: Glossary and abbreviations
Page 107 and 108: Annex 2: QBCR review form COMPARISO
Page 109 and 110: Annex 2: QBCR review form Character
Page 111 and 112: Annex 2: QBCR review form DISCUSSIO
Page 113 and 114: Annex 3: Definitions/guidelines for
Page 115 and 116: Annex 3: Definitions/guidelines for
Page 117 and 118: Annex 4: Working group Needlestick
show all

Effectiveness of measures to prevent needlestick injuries among ...

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?